POSTER PRESENTATION Open Access In vitro antifungal susceptibility of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia Nasir Tajure Wabe * , Jemal Hussein, Sultan Suleman, Kedir Abdella From 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) Marseille, France. 23-25 May 2012 Summary objective Oral Candidiasis is the most common HIV related oral lesion. Most patients are infected with a strain originally present as a commensal of the oral cavity. The chronic use of antifungal agents, in the treatment of candidiasis mainly in HIV/AIDS patients leads to the selection of strain resis- tant to this therapy. The objective of this study was to evaluate the in vitro susceptibility of Candida albicans to commonly used antifungal agents in Ethiopia. Methods In vitro susceptibility tests were performed using the broth microdilution method following the National Com- mittee for Clinical Laboratory Standards (NCCLS) M27- A guidelines. Data were then analyzed using SPSS for windows version 16.0. Tests of proportions were done with Chi-Square, and a p value of <0.05 was considered as statistically significant. Results A total of 42 oral C.albicans isolates from HIV-infected patients were included in this study. Forty one (97.7%) of all isolates were determined fully susceptible to ampho- tericin B, 40 (95.3%) to nystatin, and 39 (92.9%) to keto- conazole and miconazole. On the other hand, the isolates showed highest rates of resistance against fluconazole (11.9%) relatively. There was little difference in the antifungal susceptibilities of C.albicans isolated from patients who had a history of previous antifungal therapy compared with those who had not received antifungal treatment. Conclusion The in vitro antifungal susceptibility testing of C.albicans in this study showed relatively high resistance to commonly used azoles. As with the prescribing of any antimi- crobial agent, the use of a systemic antifungal drug must be justified. Efforts must be maintained to avoid inap- propriate or unnecessary prescribing of these antifungal. Published: 25 May 2012 doi:10.1186/1742-4690-9-S1-P44 Cite this article as: Wabe et al.: In vitro antifungal susceptibility of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia. Retrovirology 2012 9(Suppl 1): P44. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit * Correspondence: [email protected] Jimma University, Jimma, Ethiopia Wabe et al. Retrovirology 2012, 9(Suppl 1):P44 http://www.retrovirology.com/content/9/S1/P44 © 2012 Wabe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In vitro antifungal susceptibility of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia

Download PDF Report

Upload
kedir
View
215
Download
0

Embed Size (px)

Citation preview

Page 1: In vitro antifungal susceptibility of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia

POSTER PRESENTATION Open Access

In vitro antifungal susceptibility of Candidaalbicans isolates from oral cavities of patientsinfected with human immunodeficiency virus inEthiopiaNasir Tajure Wabe*, Jemal Hussein, Sultan Suleman, Kedir Abdella

From 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)Marseille, France. 23-25 May 2012

Summary objectiveOral Candidiasis is the most common HIV related orallesion. Most patients are infected with a strain originallypresent as a commensal of the oral cavity. The chronic useof antifungal agents, in the treatment of candidiasis mainlyin HIV/AIDS patients leads to the selection of strain resis-tant to this therapy. The objective of this study was toevaluate the in vitro susceptibility of Candida albicans tocommonly used antifungal agents in Ethiopia.

MethodsIn vitro susceptibility tests were performed using thebroth microdilution method following the National Com-mittee for Clinical Laboratory Standards (NCCLS) M27-A guidelines. Data were then analyzed using SPSS forwindows version 16.0. Tests of proportions were donewith Chi-Square, and a p value of <0.05 was consideredas statistically significant.

ResultsA total of 42 oral C.albicans isolates from HIV-infectedpatients were included in this study. Forty one (97.7%) ofall isolates were determined fully susceptible to ampho-tericin B, 40 (95.3%) to nystatin, and 39 (92.9%) to keto-conazole and miconazole. On the other hand, the isolatesshowed highest rates of resistance against fluconazole(11.9%) relatively. There was little difference in the anti-fungal susceptibilities of C.albicans isolated from patientswho had a history of previous antifungal therapy

compared with those who had not received antifungaltreatment.

ConclusionThe in vitro antifungal susceptibility testing of C.albicansin this study showed relatively high resistance to com-monly used azoles. As with the prescribing of any antimi-crobial agent, the use of a systemic antifungal drug mustbe justified. Efforts must be maintained to avoid inap-propriate or unnecessary prescribing of these antifungal.

Published: 25 May 2012

doi:10.1186/1742-4690-9-S1-P44Cite this article as: Wabe et al.: In vitro antifungal susceptibility ofCandida albicans isolates from oral cavities of patients infected withhuman immunodeficiency virus in Ethiopia. Retrovirology 2012 9(Suppl 1):P44.

Submit your next manuscript to BioMed Centraland take full advantage of:

• Convenient online submission

• Thorough peer review

• No space constraints or color figure charges

• Immediate publication on acceptance

• Inclusion in PubMed, CAS, Scopus and Google Scholar

• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit* Correspondence: [email protected]

Jimma University, Jimma, Ethiopia

Wabe et al. Retrovirology 2012, 9(Suppl 1):P44http://www.retrovirology.com/content/9/S1/P44

© 2012 Wabe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative CommonsAttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction inany medium, provided the original work is properly cited.

mailto:[email protected]

http://creativecommons.org/licenses/by/2.0